$22.95
2.73% yesterday
Nasdaq, Aug 01, 10:00 pm CET
ISIN
US03753U1060
Symbol
APLS

Apellis Pharmaceuticals, Inc. Stock price

$22.95
+5.08 28.43% 1M
-5.54 19.45% 6M
-8.96 28.08% YTD
-13.05 36.25% 1Y
-32.81 58.84% 3Y
-4.77 17.21% 5Y
+8.92 63.58% 10Y
+8.92 63.58% 20Y
Nasdaq, Closing price Fri, Aug 01 2025
+0.61 2.73%
ISIN
US03753U1060
Symbol
APLS
Industry

Key metrics

Basic
Market capitalization
$2.9b
Enterprise Value
$3.0b
Net debt
$95.0m
Cash
$358.4m
Shares outstanding
125.7m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
3.7 | 3.3
EV/Sales
3.8 | 3.4
EV/FCF
negative
P/B
17.6
Financial Health
Equity Ratio
25.8%
Return on Equity
-86.6%
ROCE
-29.6%
ROIC
-
Debt/Equity
2.8
Financials (TTM | estimate)
Revenue
$775.8m | $866.1m
EBITDA
$-184.4m | $-182.4m
EBIT
$-186.2m | $-212.5m
Net Income
$-223.7m | $-221.2m
Free Cash Flow
$-8.4m
Growth (TTM | estimate)
Revenue
48.0% | 10.8%
EBITDA
54.2% | -11.8%
EBIT
53.9% | -28.8%
Net Income
46.4% | -11.8%
Free Cash Flow
98.5%
Margin (TTM | estimate)
Gross
83.0%
EBITDA
-23.8% | -21.1%
EBIT
-24.0%
Net
-28.8% | -25.5%
Free Cash Flow
-1.1%
More
EPS
$-1.8
FCF per Share
$-0.1
Short interest
17.3%
Employees
708
Rev per Employee
$1.1m
Show more

Is Apellis Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,028 stocks worldwide.

Apellis Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

28 Analysts have issued a Apellis Pharmaceuticals, Inc. forecast:

18x Buy
64%
10x Hold
36%

Analyst Opinions

28 Analysts have issued a Apellis Pharmaceuticals, Inc. forecast:

Buy
64%
Hold
36%

Financial data from Apellis Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
776 776
48% 48%
100%
- Direct Costs 132 132
86% 86%
17%
644 644
42% 42%
83%
- Selling and Administrative Expenses 501 501
5% 5%
65%
- Research and Development Expense 329 329
0% 0%
42%
-184 -184
54% 54%
-24%
- Depreciation and Amortization 1.80 1.80
1% 1%
0%
EBIT (Operating Income) EBIT -186 -186
54% 54%
-24%
Net Profit -224 -224
46% 46%
-29%

In millions USD.

Don't miss a Thing! We will send you all news about Apellis Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Apellis Pharmaceuticals, Inc. Stock News

Neutral
Seeking Alpha
about 11 hours ago
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS ) Q2 2025 Earnings Conference Call July 31, 2025 8:30 AM ET Company Participants Caroline R. Baumal - Chief Medical Officer Cedric Francois - Co-Founder, President, CEO & Director David L.
Positive
Seeking Alpha
one day ago
Apellis Pharmaceuticals has made pipeline progress and strengthened its balance sheet since I looked at this biopharma name earlier this year, warranting a fresh look at the stock. Recent approvals for Empaveli for two new indications and a lucrative royalty deal with Sobi enhance future revenue potential and bolster the company's balance sheet. With solid cash reserves and projected narrowing ...
Neutral
GlobeNewsWire
2 days ago
WALTHAM, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), today announced its second quarter 2025 financial results and business highlights.
More Apellis Pharmaceuticals, Inc. News

Company Profile

Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which develops novel therapeutic compounds. It develops complement immunotherapies for the treatment of complement-dependent autoimmune and inflammatory diseases through APL-2 product. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.

Head office United States
CEO Cedric Francois
Employees 708
Founded 2009
Website apellis.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today